sdü tıp fak derg Medical Journal of Süleyman Demirel University 2602-2109 Süleyman Demirel Üniversitesi 10.17343/sdutfd.955035 Surgery Cerrahi ERKEK MEME KANSERİ CERRAHİ DENEYİMİMİZ OUR MALE BREAST CANCER SURGERY EXPERIENCE https://orcid.org/0000-0002-2133-2106 Zihni İsmail Süleyman Demirel Üniversitesi,Tıp Fakültesi Genel Cerrahi Anabilimdalı,Cerrahi Onkoloji Bilimdalı https://orcid.org/0000-0002-8834-2421 Tercan Mustafa Eskişehir Şehir Hastanesi, Cerrahi Onkoloji Kliniği https://orcid.org/0000-0002-8168-623X Bodur Muhammed Selim Süleyman Demirel Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilimdalı, Cerraahi Onkoloji Bilimdalı https://orcid.org/0000-0003-1665-3607 Turan Bilal SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI https://orcid.org/0000-0003-1813-9687 Karaca İsa SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI https://orcid.org/0000-0001-9558-6005 Erakın Mümtaz SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI, CERRAHİ ONKOLOJİSİ BİLİM DALI https://orcid.org/0000-0002-1198-1233 Çelik Girayhan SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI https://orcid.org/0000-0001-7724-9750 Sözen İsa SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI https://orcid.org/0000-0002-5549-4023 Sabuncuoglu Mehmet SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI https://orcid.org/0000-0001-8274-7973 Çetin Recep SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI, CERRAHİ ONKOLOJİSİ BİLİM DALI 06 30 2022 29 2 255 259 12 15 2021 03 07 2022 Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 1994 Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

AmaçErkek Meme Kanseri nadir görülen bir hastalıktır. İnsidansıson yıllarda artmakta, ancak sağkalım sonuçlarıiyileşmektedir. Prospektif randomize çalışmalarıneksikliği nedeniyle, kadın meme kanseri kılavuzlarınagöre tedavisi ve takibi yapılmaktadır. Ancak kendineözgü anatomi ve fizyolojisi nedeniyle hastalığın seyrindefarklılıklar olabileceği düşünülmektedir.Gereç ve YöntemSüleyman Demirel Üniversitesi Tıp Fakültesi CerrahiOnkoloji Kliniği’ nde Ocak 2011 – Ocak 2020 tarihleriarasında meme kanseri nedeniyle opere edilen erkekhastaların verileri retrospektif olarak değerlendirildi.Adenokarsinom dışındaki meme patolojileri çalışmayadahil edilmedi.BulgularÇalışmaya 7 hasta dahil edildi. Aynı süre içerisinde847 kadın hasta görülürken, erkek hasta oranı % 0,8idi. Tüm hastalara total mastektomi ile birlikte level 1,2, 3 aksiller diseksiyon yapıldı. Patoloji sonuçları değerlendirildiğinde;1 (% 14,2) hastada evre 1, 2 (%28,5) hastada evre 2, 3 (% 42,8) hastada evre 3, 1 (%14,2) hastada evre 4 hastalık olduğu görüldü. Genelsağkalım ortanca değeri 48 ay (min: 35 - max: 53 )olarak saptandı.SonuçErkek meme kanserinin aynı evredeki hastalardaprognozunun kadın meme kanserinden daha kötüolmadığı gösterilmiştir. Ancak geç tanı, tedaviyeuyumsuzluk ve standardizasyon problemleri nedeniylepratikte daha kötü prognoz söz konusudur. Erkekmeme kanseri konusunda farkındalığın artırılması veyapılacak geniş çaplı prospektif randomize çalışmalarneticesinde tedavinin erkek meme kanserine özgü,standardize edilmesi ile daha iyi sonuçlara ulaşılabileceğinidüşünüyoruz.

ObjectiveMale breast cancer is a rare disease. Its incidence hasincreased in recent years, but survival outcomes areimproving. Due to the lack of prospective randomizedtrials, it is treated and followed up according to femalebreast cancer guidelines. However, it is thought thatthere may be differences in the course of the diseasedue to its unique anatomy and physiology.Materials and MethodsThe data of male patients who were operated forbreast cancer in Süleyman Demirel UniversityMedical Faculty Surgical Oncology Clinic betweenJanuary 2011 and January 2020 were evaluatedretrospectively. Breast pathologies other thanadenocarcinoma were not included in the study.ResultsSeven patients were included in the study. During thesame period, 847 female patients were seen, while therate of male patients was % 0,8. Level 1, 2, 3 axillarydissection was performed in all patients along withtotal mastectomy. When the pathology results wereevaluated, it was seen that 1 (14,2 %) patient had stage1, 2 (28,5 %) patient stage 2, 3 (42,8 %) patient stage 3,1 (14,2 %) patient stage 4 disease. The median overallsurvival was 48 months (min: 35 - max: 53).ConclusionIt has been shown that the prognosis of male breastcancer in patients at the same stage is not worsethan female breast cancer. However, in practice,the prognosis is worse due to late diagnosis, noncompliancewith treatment and standardizationproblems. We believe that better results can beachieved by raising awareness about male breastcancer and standardizing treatment specific to malebreast cancer as a result of large - scale prospectiverandomized trials.

 erkek meme kanseri mastektomi meme kanseri breast cancer male breast cancer mastectomy [1] Romics L., O'Brien M. E., Relihan N., O'Connell F., Redmond H. P. (2009). Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. Journal of Medical Case Reports, 3(1), 13. [2] Korde L. A., Zujewski J. A., Kamin L., Giordano S., Domchek S., Anderson W. F., et all (2010). Multidisciplinary meeting on male breast cancer: summary and research recommendations. Journal of Clinical Oncology, 28(12), 2114. [3] Anderson W. F., Jatoi I., Tse J., Rosenberg P. S. (2010). Male breast cancer: a population-based comparison with female breast cancer. Journal of Clinical Oncology, 28(2), 232. [4] Leon - Ferre R. A., Giridhar K. V., Hieken T. J., Mutter R. W., Couch F. J., Jimenez R. E. et all (2018). A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 37(4), 599-614. [5] Salehi A., Zeraati H., Mohammad K., Mahmoudi M., Talei A. R., Ghaderi A., et all (2011). Survival of male breast cancer in Fars, South of Iran. Iranian Red Crescent Medical Journal, 13(2), 99. [6] Auvinen A., Curtis R. E., Ron E. (2002). Risk of subsequent cancer following breast cancer in men. Journal of the National Cancer Institute, 94(17), 1330-1332. [7] Dong C., Hemminki K. (2001). Second primary breast cancer in men. Breast cancer research and treatment, 66(2), 171. [8] Baojiang L., Tingting L., Gang L., Li Z. (2012). Male breast cancer: A retrospective study comparing survival with female breast cancer. Oncology letters, 4(4), 642-646. [9] Metin Y., Aydın İ., Mikdat B. (2016). Male Breast Cancer. J Breast Health, 12, 1-8. [10] Nahleh Z. A., Srikantiah R., Safa M., Jazieh A. R., Muhleman A., Komrokji R. (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer: Interdisciplinary International Journal of the American Cancer Society, 109(8), 1471-1477. [11] Gnerlich J. L., Deshpande A. D., Jeffe D. B., Seelam S., Kimbuend, E., Margenthaler J. A. (2011). Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in - stage migration. Annals of surgical oncology, 18(7), 1837-1844. [12] Foerster R., Foerster F. G., Wulff V., Schubotz B., Baaske D., Wolfgarten M., Rudlowski C. (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC cancer, 11(1), 335. [13] Borgen P. I., Senie R. T., McKinnon W. M., & Rosen P. P. (1997). Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Annals of surgical oncology, 4(5), 385-388. [14] Oger A. S., Boukerrou M., Cutuli B., Campion L., Rousseau E., Bussières E., et all. (2015). Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases. Gynecologie, obstetrique & fertilite, 43(4), 290-296. [15] Zongo N., Ouédraogo S., Korsaga - Somé N., Somé O. R., Naïma G. O., Ouangré E., et all. (2018). Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso). World journal of surgical oncology, 16(1), 4. [16] Bourhafour M., Belbaraka R., Souadka A., M'rabti H., Tijami F., Errihani H. (2011). Male breast cancer: a report of 127 cases at a Moroccan institution. BMC research notes, 4(1), 219. [17] Al Awayshih M. M., Nofal M. N., Yousef A. J. (2019). Modified Radical Mastectomy for Male Breast Cancer. The American journal of case reports, 20, 1336. [18] Nguyen T., Cowher M. (2012, May). Demand for breast-conserving surgery among male breast cancer patients. In Annals of surgical oncology (Vol. 19, pp. 91-92). 233 Spring St, New York, NY 10013 USA: Springer. [19] Parker P. A., Youssef A., Walker S., Basen - Engquist K., Cohen L., Gritz E. R., et all. (2007). Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Annals of surgical oncology, 14(11), 3078-3089. [20] Nordman I. C., Dalley D. N. (2008). Breast Cancer in Men—Should Aromatase Inhibitors Become First‐Line Hormonal Treatment?. The breast journal, 14(6), 562-569. [21] Mauras N., Hayes V. Y., Klein K. O. (1999). Estrogen suppression in males: metabolic effects. Pediatric Research, 45(7), 94-94. [22] Pemmaraju N., Munsell M. F., Hortobagyi G. N., Giordano S. H. (2012). Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Annals of oncology, 23(6), 1471-1474. [23] Moredo Anelli T. F., Anelli A., Tran K. N., Lebwohl D. E., Borgen P. I. (1994). Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients. Cancer, 74(1), 74-77. [24] Fentiman I. S. (2018). Surgical options for male breast cancer. Breast cancer research and treatment, 172(3), 539-544. [25] Xu S., Yang Y., Tao W., Song Y., Chen Y., Ren Y., et all. (2012). Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast cancer research and treatment, 136(2), 495-502. [26] Cloyd J. M., Hernandez - Boussard T., Wapnir I. L. (2013). Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983–2009. Annals of surgical oncology, 20(5), 1545-1550. [27] Jardel P., Vignot S., Cutuli B., Creisson A., Vass S., Barranger E., et all. (2018). Should adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review. Anticancer research, 38(1), 23-31. [28] Cardoso F., Bartlett J. M. S., Slaets L., Van Deurzen C. H. M., van Leeuwen - Stok E., Porter P., et all. (2018). Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of oncology, 29(2), 405-417. [29] Ruddy K. J., Winer E. P. (2013). Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals of oncology, 24(6), 1434-1443.